The Inflammation Stack: A Measurable Protocol
This is the rare stack you can audit. Measure hs-CRP, change one thing, re-measure at three months, and keep only what moved something.
The Short Answer
Pillar 3 has a property most Pillars lack: an inexpensive, standardised, responsive marker. That makes an inflammation stack testable rather than believed, and applying that test shrinks the stack considerably. Two compounds have reasonable human data, the sources of inflammation matter more than the suppressors, and the discipline of measuring before and after is what separates this protocol from a set of purchases.
The Sources Come First
Chronic low-grade inflammation is produced by identifiable things, and removing a source beats suppressing the signal.
Visceral adipose tissue. The largest contributor for most people with excess adiposity, since it actively secretes inflammatory cytokines. Reducing it reduces production.
Sleep restriction and sleep-disordered breathing. Restriction raises markers within days; breathing disorder contributes through intermittent hypoxia and is often unrecognised.
Physical inactivity, independent of adiposity.
Periodontal disease. Common, often asymptomatic early, contributes to systemic markers, and outside where most people look.
Sustained hyperglycaemia and glycation.
Excess alcohol and smoking.
Overtraining. The opposite failure, since the exercise relationship is U-shaped.
None of these responds to a supplement, and each exceeds the effect of any compound below. The Pillar 3 protocol covers them in sequence.
The Stack Itself
| Component | Dose | Evidence |
|---|---|---|
| Omega-3 EPA and DHA | 2 g or more combined | Best in category; also substrate for pro-resolving mediators |
| Dietary fibre | Toward 30 g daily | Short-chain fatty acids and barrier integrity; probably underrated |
| Bioavailable curcumin | Per formulation; enhanced forms only | Reasonable trials on markers and osteoarthritis symptoms |
| Vitamin D, where low | To correct status | Immune modulation; correction rather than enhancement |
| Magnesium, where intake is low | 200 to 400 mg elemental | Low intake associates with higher CRP |
| Boswellia, for joint symptoms | Standardised extract | 5-lipoxygenase inhibition; osteoarthritis data |
That is the whole defensible list. Omega-3 and curcumin carry the human evidence, fibre probably does more than either and is not usually filed here, and the rest are corrections.
Two formulation points decide whether this works. Omega-3 labels state total oil weight rather than EPA and DHA content, so a 1000 mg capsule commonly delivers around 300 mg of what matters. And curcumin trial results come from bioavailability-enhanced formulations using piperine, phospholipid complexes or micellar delivery, not from plain extract or turmeric powder.
What Fails the Bioavailability Test
A long list of polyphenols inhibits NF-kB in cell culture and does not reach those concentrations in human tissue at oral doses.
Resveratrol. Extensive conjugation leaves free plasma levels far below experimental concentrations, and human trials have been largely unimpressive.
Quercetin. Poor bioavailability, plus substantial CYP3A4 and P-glycoprotein interactions that matter for anyone on common medications and are rarely mentioned.
EGCG and green tea extract. Low absorption, and hepatotoxicity reports at high-dose extracts make this a genuine safety consideration rather than a theoretical one.
Most proprietary anti-inflammatory blends. Several polyphenols at undisclosed doses, frequently below anything studied, often acting on the same pathway.
Sulforaphane and boswellia are the partial exceptions worth watching, the former on a well-characterised Nrf2 mechanism with formulation as the limiting factor, the latter on osteoarthritis symptom data.
The general rule: when a compound's evidence is a cell-culture NF-kB result, ask what plasma concentration oral dosing achieves. For most of this category the answer settles it.
Timing Conflicts to Respect
Two timing issues in this stack are real and easily avoided.
Do not take high-dose anti-inflammatory or antioxidant compounds close to training. The reactive oxygen species produced by exercise are part of the adaptation signal, and blunting them attenuates mitochondrial and insulin sensitivity improvements in trials. Move them away from sessions rather than dropping them.
Do not suppress inflammation during acute illness or after injury or surgery. Acute inflammation is the mechanism clearing the pathogen and initiating repair. The appropriate response there is sleep, protein and rest, and pausing the stack.
Surgery specifically. High-dose omega-3, ginkgo, garlic and vitamin E all affect bleeding and should be discussed with the surgical team in advance.
Seasonal adjustment. Vitamin D requirement rises in winter at higher latitudes and falls in summer, so a fixed year-round dose is a compromise between two seasons.
The through-line is that the target is chronic low-grade inflammation, not the acute response, and confusing the two makes the intervention harmful rather than merely useless.
The Measurement Protocol
This is what makes the stack a protocol rather than a purchase.
Baseline hs-CRP, drawn away from acute illness and away from unaccustomed hard exercise by at least 48 to 72 hours. Note recent illness, training and sleep. Take two baselines a few weeks apart if a decision will hang on it, since within-person variation is substantial.
Also baseline ferritin, since it rises with inflammation and can conceal low iron; HbA1c; waist circumference; and, if not recent, a lipid panel.
Change one thing. Either a source, adiposity, sleep, activity, alcohol, or one compound. Not several.
Re-measure at three months, under the same conditions.
Interpret honestly. If hs-CRP has not moved and nothing symptomatic has changed, the change did not do what it was added for. That is a defensible reason to remove it.
If hs-CRP stays elevated against a well-executed protocol, that warrants clinical assessment rather than more compounds. Persistent elevation can reflect an unrecognised inflammatory condition, occult infection, an autoimmune process or, occasionally, malignancy.
Most people never run this loop, which is why most anti-inflammatory stacks continue for years without evidence they are doing anything.
What a Realistic Result Looks Like
Expectations are worth calibrating, because the compound contribution is modest and the source contribution is not.
A person with an hs-CRP of 3 mg/L, central adiposity and poor sleep who addresses adiposity, sleep and activity can reasonably expect a substantial fall. The same person adding omega-3 and curcumin to an unchanged lifestyle should expect a small one.
A person with an hs-CRP already below 1 mg/L has little room to move and the stack is largely redundant for that purpose, though omega-3 may still be worth taking for triglycerides and general reasons.
Symptomatic joint pain is a partially separate question, where bioavailable curcumin and boswellia have symptom data independent of any CRP change, which makes symptom improvement a legitimate endpoint there.
The honest summary of this stack: two compounds worth taking, one dietary component that outperforms both, corrections where status is low, and a measurement discipline that most of the category is designed to avoid.
The AEONNN Perspective
This is the stack AEONNN can most cleanly audit, because hs-CRP is inexpensive, standardised and responsive over three months. The Insight Protocol structure applies exactly: baseline under controlled conditions, one change, re-measure, and remove what did not move anything.
The Pharmacokinetics layer does the pruning. Cell-culture NF-kB inhibition is abundant across polyphenols and mostly unreachable at oral doses, which removes resveratrol, quercetin and EGCG from the recommendation. The Quality layer decides the two that remain: omega-3 by EPA and DHA content rather than oil weight, and curcumin only in bioavailability-enhanced formulations, since that is what the trials used.
The platform surfaces sources before suppressors, so a Pillar 3 recommendation frequently comes from Pillar 4 adiposity, Pillar 9 sleep or Pillar 6 barrier integrity. Two timing rules are enforced as sequencing rather than exclusion: away from training, since blunting the reactive oxygen species signal attenuates adaptation, and paused during acute illness or after surgery, where the inflammatory response is doing the work.
Pillar Matrix mapping
Database Matrix layers
- Evidence Layer (PubMed, Cochrane, ClinicalTrials.gov)
- Pharmacokinetics Layer (HMDB, PubChem)
- Quality / Formulation Layer (ConsumerLab, Labdoor)
- Real-Time User Layer (wearable and adherence signals)
Frequently Asked
What should an anti-inflammatory stack contain?
Omega-3 at 2 g or more of combined EPA and DHA, fibre toward 30 g daily, a bioavailable curcumin formulation for symptomatic use, and corrections for low vitamin D or magnesium.
Why do most anti-inflammatory supplements fail?
They demonstrate NF-kB inhibition in cell culture at concentrations oral dosing does not reach in human tissue. Resveratrol, quercetin and EGCG all have this problem.
Does curcumin formulation matter?
Decisively. Plain curcumin is very poorly absorbed, and trial results come from enhanced formulations using piperine, phospholipid complexes or micellar delivery.
Should I take these around training?
No. High-dose anti-inflammatory and antioxidant compounds close to a session blunt the reactive oxygen species signal that drives adaptation. Move them away from training rather than stopping them.
Should I take them when ill?
No. Acute inflammation is the mechanism clearing the pathogen and initiating repair. Pause the stack and prioritise sleep, protein and rest.
How do I know if the stack works?
Measure hs-CRP at baseline and at three months, away from illness and hard exercise. If it has not moved and symptoms are unchanged, the addition is not doing what it was added for.
What if CRP stays high despite everything?
That warrants clinical assessment rather than more compounds. Persistent elevation can reflect an unrecognised inflammatory condition, occult infection, an autoimmune process or, occasionally, malignancy.
Evidence and review
Any dosage ranges cited here reflect the ranges used in published human trials, not personal recommendations. Evidence in this field moves, so this article is reviewed quarterly and carries its last-updated date above. Nothing here is intended as medical advice, and supplementation should be discussed with a qualified clinician, particularly alongside prescribed medication or an existing condition.